Vol. 14 No. 1 (2024): December - Happy Holidays from Switzerland and a Happy New Year 2025!
Switzerland, December 2024,
Charting the Evolution of Medical Publishing and State of the Swiss Journal of Radiology and Nuclear Medicine after 18 Months of Impact - Editorial Communication
As we celebrate 18 months since the launch of the Swiss Journal of Radiology and Nuclear Medicine (www.SJORANM.com), it is both a privilege and an inspiration to reflect on the journey that has brought us to this significant milestone. Since its establishment in June 2023, the journal has rapidly grown into a dynamic platform that bridges disciplines, fosters innovation, and contributes to the global dialogue in radiology and nuclear medicine. Our presence extends beyond traditional boundaries, leveraging the reach of social media platforms such as YouTube, LinkedIn, X, TruthSocial, Facebook, Instagram, TikTok, and others. The rapidly growing number of followers on these channels underscores their potential as transformative tools for scientific communication. Unlike conventional publishing formats, these platforms enable the dissemination of scientific content not only through text but also via audio and video, offering unprecedented opportunities to engage and educate diverse audiences. This evolution mirrors other technological disruptions. Just as email rendered fax and postal mail obsolete within months of its inception, scientific publishing is poised for a similar transformation. The advent of low-cost, high-impact tools for creating and sharing content challenges the traditional publishing models, compelling established publishers to adapt or risk obsolescence. As we continue this journey, we remain committed to embracing innovation and fostering a collaborative, forward-thinking approach that ensures the Swiss Journal of Radiology and Nuclear Medicine remains at the forefront of scientific communication.
-------------------------------------------------------
Original Article from Vascular Solutions of North Carolina, USA - Case Series Analysis of Trans-Arterial Embolization for Osteoarthritis-Related Hand Pain
Osteoarthritis (OA) is a widespread disorder which commonly impacts a significant portion of the population. Although most cases involve the knee joint, it can also affect the carpometacarpal joint and cause significant pain in the hand and thumb. Traditional treatments often provide short-term pain relief and need continual treatment prompting the need for exploring alternative therapies to prolong the duration of pain relief. This case series assesses the clinical success of trans-arterial embolization (TAE) of the joints in the hand as a minimally invasive treatment for chronic pain associated with hand joint OA, defined as a 50% (or greater) decrease in Visual Analog Scale (VAS) score overall, as well as a decrease in prescribed pain medication use. We present a case report of four patients who underwent this intervention for hand joint osteoarthritis. Preliminary results show an average decrease in VAS exceeding the 50% threshold, with a notable reduction in pain medication usage and improvements in daily activities. These findings suggest that TAE shows promise as a minimally invasive therapy for hand joint OA, warranting further investigation into its long-term efficacy and safety.
